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Introduction 
Depression in late-life is one of the most prevalent and disabling disorders for the elderly. Although, 
various pharmacologic and psychosocial treatments are available, a significant portion of patients 
with late-life depression remain symptomatic or have a delayed recovery (Roose and Schatzberg, 
2005). Differentiating those who are likely to have a good or poor response to treatment may have 
useful clinical applications: i) to inform patients about prognosis; ii) to speed up treatment 
adjustment; and iii) to tailor appropriate treatments to specific patients. A predictor is a variable or 
set of variables that can determine the possible outcome of an intervention in a population 
(Nierenberg, 2003). Predictors can be identified from demographic data, clinical characteristics, and 
routine and specific investigation results.  
There are only a limited number of reviews of predictors of treatment outcome in late-life 
depression. Alexopoulos et al. (1989) reviewed the literature, and argued that the results of 
predictor studies which had used mixed-age populations might not be applicable to geriatric 
populations. They suggested that comorbid medical illness, duration of depressive episode, 
dysthymia and “double depression” (dysthymia in addition to major depression), personality 
disorder and neuroimaging abnormality predicted chronicity of a depressive episode in older adults. 
In a meta-analysis of RCTs of cognitive behavioural therapy, Gould et al. (2012) found that 
treatment-related, study design and quality-related factors (such as concurrent pharmacotherapy, 
use of an active or non-active control, type of outcome measure and selective outcome reporting), 
but not demographic or clinical variables, were associated with the magnitude of treatment 
outcome. In a patient-level meta-analysis, Nelson et al. (2013) reported three predictors that 
moderated drug- placebo differences from 10 RCTs of second-generation antidepressants in late-life 
depression; increased age, illness duration from first onset and depression severity. In their meta-
regression of 34 RCTs of antidepressants in older people with major depression, Calati et al. (2013) 
showed that male sex, increasing age, being Caucasian, less severe baseline depression and longer 
duration of episode had negative effects on the outcome of antidepressant treatment. Pimontel et 
al. (2016) found in their meta-analysis that impairments in executive functioning, specifically 
planning and organisation, were associated with poorer immediate antidepressant treatment 
response. Aizenstein et al. (2014) showed in their review that brain volume loss, lower white matter 
integrity and alteration of activity seen in fMRI in certain regions were associated with poorer 
treatment outcomes. Further, De Crescenzo et al. (2016) found in their systematic review that FDG-
PET imaging may predict treatment response to antidepressants by showing reduced glucose uptake 
in several brain areas. 
To the authors' knowledge, no recent systematic review and meta-analysis has examined predictors 
of treatment outcome in a broad range of treatments for late-life depression (including 
pharmacological, psychological, psychosocial and care management interventions). A previous 
comprehensive review of treatments was conducted in 1989 and is clearly in need of updating given 
the number of studies that have been published since then (Alexopoulos et al., 1989). The aim of this 
systematic review was to identify and critically appraise predictors of treatment outcome in RCTs of 
any intervention in comparison to active or non-active control conditions (e.g. placebo or treatment 
as usual) for late-life depressive disorder. The aim of the meta-analysis was to calculate the 
aggregated effect size of consistently reported predictors. Outcomes of interest included treatment 
response, remission or change in score on standardised depression questionnaires. 
 Method 
 
Identification of studies 
Online bibliographic databases (Pubmed, Embase, CINAHL, PsychINFO and Web of Science - all years) 
were searched on 6 December 2016. References of published reviews and studies were also 
manually searched. . The following terms were used to search the databases: 
(depress*) AND (“older adult” OR “old age” OR elder* OR geriatr* OR “late onset” OR late-onset OR 
“late life” OR late-life) AND (random* OR RCT OR “clinical trial” OR “control* trial*”) AND (predict* 
OR moderat* OR mediat* OR regress*) 
Titles and study abstracts were initially screened by CT in order to determine eligibility for retrieval. 
Retrieved articles were then screened for eligibility and selected for inclusion using a structured 
proforma. Studies were independently and blindly screened and selected by CT and co-authors 
(RLGa, HG, MC, EW, GR, TS or AT), and disagreements were resolved through discussion. Unresolved 
discrepancies were discussed with RLG. 
 
Inclusion/exclusion criteria 
Studies were included if they met the following criteria: 
1. Peer-reviewed RCT or secondary analysis of data from a peer-reviewed RCT; 
2. Any intervention (e.g. pharmacological, psychological, psychosocial or care management); 
3. Non-active (e.g. treatment as usual) or active control condition (e.g. placebo), or other 
comparative treatment condition; 
4. Sample size was greater than 5 in each condition; 
5. Participants were aged 60 or more (studies including older and younger participants were 
included only if separate analyses were conducted for older participants); 
6. Participants had diagnosis of major depression according to DSM/ICD criteria or established 
criteria; 
7. Reported statistical significant data on predictors, moderators or mediators of treatment 
outcome, specifically, treatment response, remission and/or change in the score on 
standardised depression questionnaires; 
8. In English language. 
 
Assessment of study quality 
The Quality Assessment Tool for quantitative studies from the Effective Public Health Practice 
Project (EPHPP) (Thomas et al., 2004) was used to assess study quality.  In addition, critical appraisal 
criteria were developed in order to assess the quality of predictor analyses (and hence findings), 
based on a systematic review by Knopp et al. (Knopp et al., 2013; Pincus et al., 2011; Sun et al., 
2012) . These criteria were: 
1. Whether the predictors were assessed by a validated assessment tool as the validity and 
reliability of the assessment tools will ensure the accuracy of the predictors; 
2. Whether the predictors were measured before randomisation or delivery of the intended 
intervention as some baseline factors may change after the allocation or be changed by the 
awareness of allocation; 
3. The number of tested predictors was less than 5 as the fewer factors analysed, the greater 
reliability and credibility to accept or reject the predictors; 
4. Whether there was a hypothesis in relation to the predictors as the selection of analysed 
factors should be based on theory or evidence in order to confirm meaningful predictors; 
5. Whether there was an analysis of interactions between predictors and treatment arms as 
this may reveal underlying moderator effects. 
Studies were independently and blindly rated by CT and co-authors (RLGa, HG, MC, EW, GR, TS or 
AT), and disagreements were resolved through discussion. Unresolved discrepancies were discussed 
with RLGo. 
Data extraction 
Data on a range of clinical and research characteristics were extracted using a structured proforma. 
Data were extracted independently and blindly by CT and co-authors (RLGa, HG, MC, EW, GR, TS or 
AT), and disagreements were resolved through discussion. Unresolved discrepancies were discussed 
with RLGo. Original studies were also retrieved and data extracted if studies of secondary data 
analyses provided insufficient information. 
 
Meta-Analysis 
Effect size 
Predictors included in the meta-analysis were reported by at least 3 studies from the systematic 
review. For each study, odds ratios or information that could be used to calculate odds ratios were 
independently extracted by two authors (CT and KK). Any disagreements were resolved through 
discussion. Studies were excluded from the meta-analysis if insufficient data were reported to 
calculate odds ratio effect sizes. The effect size of interest was the overall effect size that included 
information from both treatment and comparison arms to reflect a difference in outcome for each 
predictor. Odds ratios were selected as the effect size of choice for this review for two reasons: i) it 
was the most frequently reported effect size in the included studies (18 out of 36 studies); and ii) 
conversion of odds ratios into other effect sizes tends to result in over- or under-estimation of effect 
sizes (Lipsey and Wilson, 2001). Odds ratios were obtained through direct extraction from included 
studies, calculations from factorial tables or conversions from other reported effect sizes. Results 
from studies that only reported statistical outcomes were converted into standardised mean 
differences using an effect size calculator (Wilson, 2001), and then converted to odds ratio using 
Hasselblad and Hedges’ method (Hasselblad and Hedges, 1995). This has been shown to be the most 
robust method for this type of effect size conversion (da Costa et al., 2012) .  
Statistical analysis 
Only predictors that were reported in 3 or more different studies were included in the meta-analysis. 
If studies reported more than one type of outcome measure for the same predictor, only one 
outcome was extracted. These were prioritised in the following order; remission, response (i.e. 
percentage reduction in score) and score or categorical outcome (e.g. high persistent, high decline 
and low decline). Remission was prioritised because it often reflects the use of more rigorous criteria 
and longer term improvement of symptoms than response, or changes in score or category of 
severity.  
Separate meta-analyses were conducted for predictor variables that were reported in at least 3 
different studies. Odds ratios were log-transformed for input into meta-analyses and back-
transformed for reporting purposes. Random-effect models were used to aggregate the effect sizes 
(DerSimonian and Laird, 1986). Statistical significance of the estimated overall odds ratio in each 
meta-analysis was examined using the Z test. Cochran’s Q-test of heterogeneity and I2 statistic were 
calculated to examine between-study variability due to heterogeneity rather than sampling error or 
chance. Values of 0, 25, 50 and 75% indicated no, low, moderate and high heterogeneity 
respectively (Higgins et al., 2003). Publication bias was estimated using Egger’s regression 
asymmetry test, which is suitable for small numbers of studies (Egger et al., 1997). If publication bias 
was detected, a nonparametric trim-and-fill method was used to impute missing studies and re-
estimate the pooled effect size (Duval and Tweedie, 2000) . An alpha level of 0.05 was used for tests 
of the estimated overall odds ratio and publication bias, while 0.10 was used for tests of 
heterogeneity due to reductions in sensitivity of Cochran's Q test with small numbers of studies. 
Using the same procedures as above, subgroup analyses were performed in order to examine 
whether any between-study heterogeneity could be explained by type of treatment. Differences in 
overall effect sizes between subgroups were assessed using a test of heterogeneity. Bonferroni-
corrections were applied to alpha levels in order to control for the risk of false positives across 
multiple subgroup analyses. Data were analysed using Stata 14.0 (StataCorp, College Station, TX). 
 
Results 
As shown in the PRISMA flow diagram (Figure 1), 6,706 articles were identified through database 
searches and 19 additional articles were identified from manual searches of related reviews. After 
removing duplicates, 4,869 articles were initially screened. The full-texts for 207 articles were 
retrieved and further screened for eligibility. 67 articles were selected after screening. 
Demographic and clinical characteristics 
Demographic and clinical characteristics were variable across studies, and some data could not be 
extracted for several studies (Table 1). About half of the studies included 100-500 participants, with 
7 studies including more than 500 and 3 studies including more than 1000. The majority of studies 
included participants with a mean age greater than 70 (38/67), who were female and of white 
ethnicity. The Mini-Mental State Examination, a brief cognitive screening tool, was used to screen 
for dementia in most of the studies (49/67). Most of the included studies used the Hamilton 
Depression scale in recruitment and monitoring the participants (63/67), and the majority included 
participants with moderate to severe depression (25/67 with 15 not available).  
Study characteristics 
Eligible studies shared considerable similarities with respect to study characteristics (see Table 2). 
Studies were published from 1994 to 2016. Most of the studies used DSM-related diagnostic criteria, 
only 4 used other diagnostic systems. Treatment in the majority of studies comprised antidepressant 
medications (38/67); in addition, 19 studies involved a care management intervention and 15 studies 
investigated psychological treatments. Further, 37 studies utilised placebo or treatment-as-usual as 
control conditions; 30 studies used different antidepressants, biological or psychosocial 
interventions as comparator conditions. Most of the included studies involved secondary data 
analyses (45/67); only 22 examined predictors in their primary analyses. 40 studies had a duration of 
follow-up of 12 weeks or less, and only 12 studies monitored participants for at least 1 year. 
Quality assessment 
As shown in Table 3, the components of the quality assessment tool that were most adequately 
addressed were study design, data collection methods, confounders and selection bias. The least 
adequately addressed component was intervention integrity. All studies received a strong rating for 
study design as only RCTs were included in the review. 98.5%, 95.5%, 88.1% and 83.6% of studies 
had a moderate to strong rating for data collection methods, analysis, confounders and blinding, 
respectively. In contrast, 71.6% of studies had a moderate to strong rating for selection bias, and 
withdrawal and drop-outs. Furthermore, the majority of studies (68.7%) received a weak rating for 
intervention integrity, which involved assessing whether participants receiving the allocated 
intervention, measurement of intervention consistency and intervention contamination control. 
Critical appraisal of the quality of predictor analyses showed that most studies generally reported 
satisfactory analyses (see Table A in the Appendix). 97.0% of studies used validated assessment tools 
to assess predictors. 76.1% had measured predictors before randomisation or receiving intervention. 
56.7% had analysed less than 5 predictors and 70.2% had an a priori hypothesis in relation to the 
predictors. However, only 46.3% of studies tested for an interaction between predictors and 
treatment type.  
Predictors of treatment outcome 
Statistically significant predictors of treatment outcomes (with respect to treatment response, 
remission and/or change in depression scores) are reported in Table 3. Although 65 different 
statistically significant predictors were identified, only 7 were reported by at least 3 studies. These 
predictors were age, baseline depression severity, early improvement, current episode duration, 
baseline anxiety symptoms, physical illness and set shifting in the trail making test. Nine predictors 
were reported by two studies, and 49 predictors were reported by only one study. 
The types of treatment that were examined in the studies that reported these 7 predictors are 
illustrated in Figure 2. The same type of relationship between treatment outcome and the predictor 
variable (i.e. positive or negative) was reported for all predictors, with the exception of age and 
baseline depression. 
Meta analyses 
Only five out of the seven above predictors were submitted to meta-analyses due to insufficient data 
to calculate effect sizes for two predictors (early improvement and current episode duration). Out of 
the five predictors submitted to meta-analyses, baseline anxiety, baseline depression and the trail 
making test were the only predictors that remained statistically significant after effect size 
aggregation (see Table 4). Physical illness showed a marginal significant effect in the meta-analysis. 
However, high levels of heterogeneity were found in all meta-analyses, with the exception of the 
trail making test. Furthermore, a statistically significant publication bias was found in the meta-
analysis of baseline anxiety, baseline depression and physical illness. However, the pooled effect size 
remained unchanged after adjusting for publication bias using a trim-and-fill method. 
Subgroup analyses 
Predictor variables submitted to meta-analyses were additionally submitted to subgroup analyses 
organised by treatment type (biological vs. psychosocial vs. biological plus psychosocial). The 
biological sub-group consisted of pharmacological treatment and rTMS/ECT trials, the psychosocial 
group comprised psychological treatment trials, and the biological plus psychosocial group consisted 
of care management and combined treatment trials. After correcting for multiple comparisons, 
significant differences were found in subgroup analyses comparing type of treatment for age, 
baseline depression, baseline anxiety and physical illness, but not executive functioning (Table 5). 
Pooled effect sizes were mostly small to moderate in magnitude, with a considerable degree of 
within-group heterogeneity.  
Discussion 
Of the 65 statistically significant predictors identified from 67 studies of RCTs, only 7 were reported 
in at least 3 studies and only 5 of these provided sufficient information to permit a quantitative 
evaluation of effect sizes in meta-analyses. These will now be addressed in turn: 
 
Age 
Older age, as a predictor of treatment outcome, is controversial in our findings. Of the 6 studies 
reporting this variable, 4 reported a negative predictor relationship between age and outcome (the 
older the age, the poorer the outcome), while two studies reported a positive relationship. The 
study that reported a positive relationship showed a greater speed of response with older age but 
not overall response rate. Although, it would generally appear that older age is a negative predictor 
of good treatment outcome, which corresponds with previous meta-regression analyses (Calati et 
al., 2013), our meta-analysis failed to show a statistically significant pooled effect size. A high level of 
heterogeneity may have been caused by variations in treatment modalities (e.g. pharmacotherapy, 
psychotherapy and care management) and outcome definitions. The subgroup analysis showed that 
older age had a small to moderate significant effect on the outcome, but only in biological treatment 
trials. Studies have suggested that age-related brain changes may lower the response to 
interventions through various mechanisms. For example, Meltzer et al. (2001) demonstrated that 
serotonin-1A receptor density was decreased in healthy older adults compared with healthy younger 
adults, which may slow or reduce the effect of drugs targeting serotonin transmission. Nahas et al. 
(2004) also reported that frontal lobe atrophy with advancing age reduced the effect of rTMS 
treatment. Further, Ribeiz et al. (2013) found that reduced gray matter volume in the orbitofrontal 
cortex was associated with poorer antidepressant response in elderly patients, which suggests that 
treatment response may partly depend on the integrity of emotional regulation. In conclusion, older 
age may be a negative predictor of treatment outcome, especially in biological treatment trials, 
which can be explained by established age-related brain changes such as brain atrophy and 
serotonin receptor density reduction. 
 
Baseline depression severity 
Baseline depression severity was the most frequently reported statistically significant predictor in 
our systematic review, despite some inconsistencies among the studies. It was reported in 16 studies 
which used two different methods to identify predictors; the first involved examining overall 
treatment outcome, and the second focused on the effect of the intervention in order to delineate 
the drug-placebo difference. 
When examining overall treatment outcome, 13 out of 16 studies reported a negative prediction 
relationship between baseline depression severity and treatment outcomes (the higher the baseline 
severity, the poorer the outcome). In addition, most of the studies reported this for remission.  
Several possibilities have been suggested to explain this association. First, Ackerman et al. (1997) 
commented that it is easier to reach an endpoint if you start with a lower baseline score of 
depression. Second, Nasser and Overholser (2005) observed that perceived social and emotional 
supports were associated with reduction of depression, and more severe depression might reduce 
access to these perceived supports, which may further diminish treatment response. Third, more 
permanent or severe underlying pathology may underlie more severe baseline depression, which 
may lessen the effect of treatment.  
For analyses that focused on the drug-placebo difference, only 3 studies reported a positive 
direction for response and depression score, but not remission. Patients with a higher baseline 
depression severity demonstrated more of an antidepressant effect compared to placebo. This 
association has been suggested to be due to those with higher baseline severity having greater room 
for improvement than those with lower baseline severity (Kirsch et al., 2008; Roose et al., 2004a).  
A meta-analysis of 14 studies showed a small, but statistically significant overall effect size in 
negative direction for this predictor. However, high levels of heterogeneity were also found and 
therefore caution must be expressed when interpreting these results. The subgroup analysis showed 
that baseline depression was significantly associated with poorer outcome, but only in biological plus 
psychosocial treatment trials. However, the analysis also showed high levels of within-group 
heterogeneity. Our findings were different from other meta-analysis studies because we looked at 
the predictor’s effect on overall outcome, whereas others focused on the predictor’s effect on the 
differences between intervention and comparison groups. Locher et al. (2015) did not find a 
relationship between baseline severity and change in symptoms in either antidepressant or placebo 
group in their meta-analysis. However, the study did not consider treatment duration in their 
analysis and limit to antidepressant studies, which may have produced the non-significant result. By 
contrast, two meta-analysis studies (Khan et al., 2005) showed that more severe baseline depression 
was associated with a higher response rate to treatment, and therefore larger treatment effect in 
patients who had a longer illness duration. Calati et al. (2013) suggested that a higher baseline 
depression group may have a better chance to reach the proportional reduction threshold than a 
lower baseline group. In conclusion, we found that higher baseline depression severity may be 
associated with poorer outcome in overall treatment. However, previous meta-analysis studies 
indicated that higher baseline depression may relate to more pronounced intervention effects than 
lower severity, though the reasons for this are unclear. 
 
Early improvement 
Early improvement was reported in 3 studies as a positive predictor of treatment outcomes. The 
range of what was considered as the early improvement period was from 1 week to 3 weeks. 
However, Volz et al. (1995) suggested that the predictive value of early improvement on treatment 
outcome may be small. Rodin and Voshart (1986) noted that an abrupt and transient improvement 
was associated with placebo response; however, gradual and persistence improvement was 
associated with antidepressant treatment. Donovan et al. (1994) also observed that a significant 
portion of patients who did not respond to antidepressant in 4 weeks finally improved after 6 weeks 
of treatment which indicated low specificity of prediction. Thus, although early improvement was 
statistically identified as a predictor, its clinical value may be limited. It was not possible to submit 
this predictor to meta-analysis due to insufficient data. 
 
Current episode duration 
Current depressive episode duration was reported in 3 studies as a negative predictor; with longer 
episodes being associated with poorer outcome. This predictor has been reported in several studies, 
but the explanation was limited (Alexopoulos et al., 1989; Calati et al., 2013; Goodkind et al., 2016; 
Moller et al., 2010; Pimontel et al., 2012). Keller et al. (1986) suggested that episode duration was an 
intrinsic feature of each individual patient. As for baseline severity, a more permanent, chronic 
condition or severe underlying pathology may underlie a longer duration, which may lessen the 
effect of treatment and hence be associated with poorer response. Again, a meta-analysis was not 
conducted for this predictor due to insufficient data. 
 
Baseline anxiety symptoms 
Baseline anxiety symptoms were consistently reported in 7 studies as a negative predictor of 
treatment outcome. Furthermore, one additional study reported symptoms of worry and panic as a 
negative predictor too. A meta-analysis of 7 studies showed a statistically significant small to 
moderate negative overall effect size for this predictor. However, high levels of heterogeneity and 
statistically significant publication bias were also found and therefore caution must be expressed 
when interpreting these results. In the subgroup analysis, baseline anxiety was significantly 
associated with poorer outcome in biological treatment trials, but not biological plus psychosocial 
treatment trials. This finding is consistent with other reviews (Goodkind et al., 2016; Moller et al., 
2010; Pimontel et al., 2012). Although, Nelson et al. (2009) reported that anxiety symptoms were 
not associated with the effect of antidepressant when compared to placebo, patients with comorbid 
anxiety symptoms had lower remission rates than the non-anxious group. Although overlapping 
genetic and neurobiological factors of depression and anxiety have been reported in previous 
studies (Morimoto et al., 2012; Morimoto et al., 2011), more recent brain imaging studies have 
showed more distinct features between depression alone and depression with anxiety symptoms. 
For example, Canu et al. (2015) revealed that patients with depression and anxiety may have more 
severe cortical atrophy in areas that correspond with anxiety symptoms than patients with 
depression alone. Potvin et al. (2015)  suggested that anxiety may be associated with smaller cortical 
thickness in the elderly. Furthermore, Domschke et al. (2010) found that the neuropeptide Y gene, 
which was found in anxious depressed patients, affected antidepressant treatment response, and 
Baffa et al. (2010) observed that serotonin gene variation influenced antidepressant treatment 
response in this group of patients. Based on these distinct clinical pictures and biological evidence, 
Ionescu et al. (2013) suggested a differentiation between anxious depression and non-anxious 
depression. Late-life depression patients with anxiety symptoms may have more severe brain 
pathology or genetic vulnerabilities that reduce the effect of treatment. Co-morbid anxiety 
symptoms were associated with poorer outcome and may be an important sign that the patient 
needs additional treatment or will have a longer time to remission.  
 
Physical illness 
Physical illness (e.g. overall comorbidity diseases and chronic illnesses such as hypertension, 
diabetes, cancer and renal disease) were consistently reported as a negative predictor in 6 studies. 
In addition, 5 studies reported pain, cerebrovascular disease, limitation of physical function and 
dyspnoea-related disability to be negative predictors of treatment outcomes. By contrast, one study 
reported that headache before receiving treatment was related to better treatment response. A 
meta-analysis showed a very small and marginal statistically significant pooled effect size, in 
conjunction with a high level of heterogeneity. Although the subgroup analyses showed a significant 
difference between treatment types, this result should be interpreted with caution given that 4 out 
of 5 studies were biological plus psychosocial treatment trials. Physical illness may complicate 
depressive outcome through both biological and psychological pathways. Illnesses that directly 
affect the brain may interrupt neurotransmitter and neural network pathways, and non-neurological 
illness may indirectly affect the brain via inflammatory process and HPA axis regulation (Brown et al., 
2004; Marson et al., 1997). Furthermore, illnesses that result in disability and pain may induce 
additional psychological stressors such as lowered self-esteem, dependency, prolonged discomfort 
and loss of social relationships (Rackley and Bostwick, 2012; Rodin and Voshart, 1986). In addition, 
depression may affect the course and incident of medical illnesses such as cardiovascular diseases, 
neurological diseases, diabetes and HIV (Marson et al., 1997). Thus, physical illness may be a 
predictor of treatment outcome that not only influences depression prognosis but also is affected by 
depression. 
 
Executive functioning 
Performance on the Trail Making Test, particularly the ability to perform the set shifting task, was 
consistently shown to positively predict depression outcomes in 3 recent studies. In addition, the 
meta-analysis showed a moderate statistically significant effect size, with no evidence of 
heterogeneity or publication bias. No significant difference was found between treatment types in 
subgroup analyses for this predictor. However, this finding was contradicted in a recent cohort study 
in which the Trail Making Test was not associated with likelihood of remission (Clery-Melin and 
Gorwood, 2017). This contradiction may be explained by the fact that the cohort study was done in 
adult population and low number of participants who completed the predictor assessment (25%).  In 
addition, performance on other executive functioning tests might predict treatment outcome. Two 
studies showed that impairment in response inhibition in the Stroop test was related to worse 
outcome, and another study reported that higher scores on a coding task and processing speed were 
related to better outcome. This result is not supported by a recent meta-analysis which showed that 
only performance on planning and organisation tasks was related to treatment response (Pimontel 
et al., 2016). However, this meta-analysis only included studies of acute (6- 12 weeks, mean 9.75 
weeks) treatment outcome of antidepressants, whereas the current review included studies with 
much longer treatment durations (8-96 weeks, mean 26.00 weeks ) in various treatment conditions. 
Another meta-analysis review showed that only the Initiation-Perseveration subscale of the Mattis 
Dementia Rating scale, a verbal fluency test, was associated with antidepressant response 
(McLennan and Mathias, 2010). A cohort study showed that Wisconsin Card Sorting Test, but not 
verbal fluency or Stroop test, was associated with response to cognitive behavioural treatment 
(Goodkind et al., 2016). These inconsistencies in evidence in older patients may lead to the 
explanation that different executive function tasks specifically predict different treatment 
conditions.  
Changes in frontal brain regions and neural networks may underlie the relationship between 
executive functioning and treatment outcome in late-life depression. For example, Alexopoulos et al. 
observed that patients with late-life depression who had impairment in executive functioning had 
poorer depression outcome (Alexopoulos et al., 2005b; Alexopoulos et al., 2002). Furthermore, the 
impairment was linked to lower frontal subcortical and limbic volume. Patel et al. (2015) reported 
that patients with late-life depression who had lower functional connectivity in the dorsal default 
mode network had better treatment outcome. Karim et al. (2016) reported differences in brain 
activity in frontal and temporal cortices involving the anterior salience network and default mode 
network between remitted and non-remitted late-life depression patients. Therefore, intact 
executive function may indicate less severe pathology or preserved ability to respond to treatment. 
 
 
Clinical and research implications 
Predicting treatment outcome in late-life depression may aid clinicians in three ways: i) it may serve 
as a useful guide to seek out information that can be used to inform and influence clinical decisions; 
ii) it may aid better decision making (e.g. whether to switch or augment treatment); and iii) it may 
better inform patients about the possible prognosis. Identifying patients with good and poor 
outcomes with these predictors may lead to better understanding of the nature of late-life 
depression and new treatment options. However, current data on each predictor is still scarce. 
Further evidence of the validity and effect of these predictors is required, in addition to replications 
of these data. Further investigation of how predictors may be integrated into clinical practice to aid 
decision making is essential for the development of new treatments that could improve 
effectiveness for patients with poorer outcomes. 
 
Strengths and limitations 
The main advantage of this systematic review is the broad range of interventions for late-life 
depression that were considered, thus providing a comprehensive summation of the literature. The 
benefit of using data from RCTs is the low rate of data attrition that can cause observational bias in 
other types of studies. 
However, there were a few limitations in this systematic review. Studies that were included were 
limited to data from peer-reviewed RCTs, rather than from grey literature such as clinical trials 
databases. Thus, this review may be subject to publication bias. A wider search including grey 
literature may have identified additional relevant studies to include in the review, although this may 
have introduced further bias as unpublished studies may be of lower methodological quality (Egger 
et al., 2003). Furthermore, 67% of included studies were secondary analyses, which questions the 
statistical validity of the predictors that we have identified. For example, secondary analyses may 
have failed to detect statistically significant predictor variables simply due to being underpowered 
for these analyses. The analysis methods employed by different studies also varied, and so caution 
should be applied when interpreting the validity of the predictors as a group. However, the fact that 
the majority of studies used regression analysis may lessen this concern. 
There were also a few limitations in the meta-analysis. A selection bias may have been introduced as 
studies were only included if they reported statistically significant predictors. Furthermore, small 
number of studies reported for each predictor variable, coupled with a variety of treatment 
modalities introduced high levels of heterogeneity. Therefore, although the results of the meta-
analyses may be of clinical value, they should be interpreted with caution. Subgroup analyses 
examined whether any between-study heterogeneity in effect sizes could be explained by the type 
of treatment. However, these analyses were limited by small numbers of studies and considerable 
heterogeneity within at least one subgroup for each predictor. Furthermore, although significant 
subgroup differences were found for these predictors, the possibility that a moderating variable 
other than treatment type may have been responsible for these differences cannot be ruled out. 
 
Conclusions 
In this systematic review, we found that older age, higher baseline depression severity, slower 
improvement, longer current episode duration, higher co-morbid baseline anxiety symptoms, the 
presence of physical illness and impairment of executive functioning are predictors of poor 
treatment outcomes. Of these seven predictor variables identified in 3 or more studies, meta-
analyses confirmed that baseline depression, baseline anxiety, physical illness and executive function 
and were significantly associated with treatment outcome. Subgroup analyses found differences in 
predictor effect between biological treatment trials, psychosocial treatment trials and biological plus 
psychosocial treatment trials. Other statistically significant predictors were identified from eligible 
studies, but there were very few replications of these predictors. These results come from post-hoc 
analyses of RCT data which may question the validity of these conclusions.  
  
Figure 1: PRISMA Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from:  Moher et al. (2009) 
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Figure 2: Bar chart of predictors reported in 3 or more studies, stratified by treatment type. 
 
Age
Baseline depression
Early improvement
Current episode duration
Baseline anxiety
Physical illnesses
Trail making test
Negative 
pharmacologic psychotherapy care management rTMS / ECT combined
pharmacologic psychotherapy care management rTMS / ECT combined
Positive 
14 12 10 8 6 4 2 0 2 4 
Figure 3: Forest plot of each predictors included in the meta-analysis 
 
  
Table 1: Demographic and clinical characteristics 
Study year 
country 
Old 
age 
sample 
size 
Mean 
age 
Mean 
years of 
education % women 
% white 
ethnicity 
Screening tool 
and mean 
cognitive score 
Depression 
Rating 
scale name 
Depression 
Rating 
scale 
criteria  for 
ENTRY 
Mean 
depressive 
severity at 
ENTRY 
Mean 
age of 
onset 
duration 
of illness 
at enter 
(wk) 
Ackerman 1997 
US 
671 N/A N/A N/A N/A MMSE (N/A) HAMD17 16 N/A N/A N/A 
Ackerman 2000 
US 
671 N/A N/A N/A N/A MMSE (N/A) HAMD17 16 N/A N/A N/A 
Adeoye 2000  
US 
15 69.2 N/A 53.33 93.33 N/A HAMD 15 19.06 N/A N/A 
Alexopoulos 2005 
US 
215 N/A 12.79 71.57 67.55 MMSE (27.35) HAMD 18 18.8 N/A N/A 
Alexopoulos 2014 
US 
138 70.95 13.37 65.94 N/A MMSE (27.4) HAMD17 14 19.05 N/A N/A 
Alpert 2003  
US 
22 67.28 N/A N/A N/A N/A HAMD24 18 24.3 N/A N/A 
Andreescu 2007 
US 
170 76.68 12.95 64.75 92.04 MMSE (N/A) HAMD17 15 20.64 61.94 109.38 
Andreescu 2009 
US 
166 76.63 13.03 65.06 92.77 MMSE (N/A) HAMD17 15 core item 
subscale 
7.08 
61.85 109.63 
Azar 2011 
US 
792 73.63 * 32.45 37.25 N/A CES-D N/A 28.31 N/A N/A 
Banerjee 1996  
UK 
69 80.71 N/A 82.61 N/A N/A MADRS N/A 26.25 N/A N/A 
Bao 2011  
US 
396 * * 70.89 65.17 MMSE (N/A) CES-D 20 20.54 N/A N/A 
Beaudreau 2015 
US 
46 70.78 15.78 65.2 69.6 MMSE (N/A) HAMD 20 22.54 N/A N/A 
Bjolseth 2015 
Norway 
73 74.81 N/A 53.42 N/A MMSE (27.59) HAMD17 18 24.72 N/A 28.4 
Bogner 2007  
US 
599 70.3 12.8 71.6 70.2 MMSE (27.4) HAMD24 N/A 17.28 N/A N/A 
Bogner 2012  
US 
599 70.2 12.8 72% 70.2 MMSE (27.4) HAMD24 10 N/A N/A N/A 
Bondareff 2000 
US 
210 67.85 * 59.04 93.81 MMSE (N/A) HAMD24 18 24.75 48.65 156† 
Cappeliez 2007 
Canada 
68 N/A * 67 N/A Physician's clinical 
judgment (N/A) 
SCL-20 N/A 1.675 N/A N/A 
Chan 2013 
Singapore 
26 69.7 * 80.8 0 N/A GDS-15 4 7.16 N/A N/A 
Chan 2014 
Singapore 
29 * * 79.3 0 N/A GDS-15 4 5.47 N/A N/A 
Coon 2003  
US 
58 66.6 14.6 68.25 N/A MMSE (N/A) HAMD 15 N/A N/A N/A 
Evans 1997b  
UK 
82 80.4 N/A 75.61 N/A MMSE (*) HAMD17 N/A 20.75 N/A N/A 
Eyre 2016 US 35 69.18 15.12 56.94 N/A MMSE (28.39) HAMD24 16 18.86 40.17 N/A 
Fields 2012  
US 
449 75.1 * 46.5 94.2 3-MS (94) GDS 6 8.7 N/A N/A 
Gasto 2003  
Spain 
68 70.83 N/A 63.24 N/A MMSE (N/A) HAMD17 21 26.52 N/A N/A 
Ghesquiere 2014 
US 
417 70.02 12.86 71.46 70.05 MMSE (N/A) CES-D 20 17.95 N/A 202.24† 
Gildengers 2002 
US 
323 70.3 12.3 72.8 91.3 MMSE (28.1) HAMD17 15 22.1 N/A 22 
Gilman 2013  1226 * * 70 69.5 MMSE (N/A) CES-D 20 11.4 N/A N/A 
US 
Greenlee 2010  
US 
124 72.29 N/A 68.35 N/A MMSE (N/A) HAMD17 15 18.48 N/A 131 
Heun 2013  
multi centres 
222 71.84 N/A 68.96 N/A MMSE (29.17) HAMD17 22 26.77 N/A 22.84 
Hsu 2016  
US + Canada 
168 66 14 57 88 MMSE (N/A) MADRS 15 28 40 104 
Jorge 2008 US 92 63.67 13.89 55.43 N/A MMSE (28.1) HAMD 17 N/A 18.57 N/A N/A 
Kaneriya 2016  
US + Canada 
181 67.36 14.16 56.91 87.87 MMSE (N/A) MADRS 15 23.26 N/A N/A 
Katon 2010  
US 
871 71 N/A 63.83 78.64 Six item cognitive 
screener (N/A) 
SCL-20 N/A N/A N/A N/A 
Kin 1997  
multi centres 
95 69.68 N/A 70.34 N/A MMSE (28.68) HAMD17 18 23.5 N/A N/A 
Kok 2009a 
Netherlands 
82 72.24 N/A 72.84 N/A MMSE (25.93) MADRS 20 32.83 N/A 22.04† 
Kok 2009b 
Netherlands 
81 72.21 N/A 72.84 N/A MMSE (25.89) MADRS 20 32.9 N/A 21.76† 
Koran 1995  
US 
671 68.6 N/A 55 94 MMSE (29) HAMD 21 16 N/A N/A N/A 
Korte 2012 
Netherlands 
202 63 * 76.7 N/A N/A CES-D 10 20.5 N/A N/A 
Krahn 2006  
US 
1531 73.9 * 30.7 45.1 Short form health 
inventory (37.6) 
CES-D N/A 24.95 N/A N/A 
Krishnan 2001  
US 
220 67.99 N/A 61.83 N/A MMSE (28.54) HAMD 24 18 24.86 N/A N/A 
Laidlaw 2008  
UK 
40 74 10 72.5 N/A MMSE (28.125) HAMD24 24 11.6 N/A N/A 
Mavandadi 2007 
US 
524 73.77 N/A N/A N/A N/A CES-D N/A 23.69 N/A N/A 
Morse 2005  
US 
160 67.7 * 75 92.5 MMSE (29.3) HAMD 17 22.5 47.9 N/A 
Mulsant 2001 
US 
116 72.1 N/A 71.6 86.2 MMSE (56.5) HAMD17 15 22.4 60.6 26 
Murphy 2013 
US 
246 71.85 N/A 51.62 N/A MMSE (28.7) HAMD17 18 22.3 N/A * 
Narushima 2010 
US 
43 62.85 14.07 58.05 97.66 MMSE (27.82) HAMD17 14 16.59 N/A N/A 
Navarro 2001 
Spain 
58 70.69 N/A 63.8 N/A MMSE (26.64) HAMD 21 26.76 66.07 6.71 
Rapaport 2003  
US 
319 69.96 N/A 56.11 95.29 MMSE (N/A) HAMD17 18 22.17 N/A 180.96† 
Raskin 2008 
Canada 
311 72.83 N/A 59.48 78.14 MMSE (22.86) HAMD17 18 18.83 N/A 55.67 
Riebe 2012 
 US 
906 71 * 56.1 78.3 Six item cognitive 
screener (N/A) 
SCL-20 N/A * N/A N/A 
Roose 2004  
US 
174 79.6 13.8 58.1 N/A MMSE (28) HAMD24 20 24.3 68.3 12.82 
Rosenthal 2005 
US 
34 66 N/A N/A 85 MMSE (N/A) BDI N/A N/A 36 N/A 
Salloway 2002  
US 
170 75.88 N/A sertraline 
41%, 
citalopram 
61% 
85 MMSE (N/A) HAMD17 18 23.09 62.77 N/A 
Sarginson 2010a 
US 
246 74.2 N/A 51.22 91.87 MMSE (N/A) HAMD17 18 22.35 N/A N/A 
Sarginson 2010b 
US 
246 74.2 N/A 51.22 91.87 MMSE (N/A) HAMD17 18 22.33 N/A N/A 
Schweizer 1998 
US 
177 72 N/A 53 N/A N/A HAMD 17 18 24.03 60 * 
Singh 1997  
US 
32 70.94 14.37 62.5 N/A MMSE (28.5) BDI 12 19.94 N/A 118.4† 
Smagula 2016  
US 
181 66 14 57 88 N/A MADRS 15 28 40 104 
Small 1995  
US 
671 N/A N/A N/A N/A MMSE (N/A) HAMD17 16 N/A N/A N/A 
Sneed 2007  
US 
174 79 * 58 N/A MMSE (N/A) HAMD24 20 24 68 N/A 
Sneed 2008  
US 
84 79 N/A 54 N/A MMSE (28.42) HAMD24 N/A 24.4 N/A N/A 
Sneed 2011  
US 
38 66 15.7 63 N/A MMSE (27.5) HAMD24 16 24.32 46.5 N/A 
Steffens 2006  
US 
1684 70.9 N/A 66.3 76.7 Six item cognitive 
screener (5.55) 
SCL-20 N/A 1.68 N/A N/A 
Tan 1994  
UK 
63 80 N/A 66.33 N/A AMT (N/A) GDS 15 16.8 N/A N/A 
van Schaik 2006 
Netherlands 
143 67.93 * 69.48 N/A MMSE (26.35) MADRS N/A 19.35 * N/A 
Volz 1995 
Germany 
189 68 N/A 75.13 N/A N/A HAMD N/A 26.2 N/A N/A 
Zanetidou 2016 
Italy 
121 75.14 * 71.11 N/A MMSE (26.87) HAMD17 18 20.14 N/A N/A 
 
Note: N/A = not applicable or not available, * = data in categorical form, † = data calculated from months or years to weeks by multiply by 4 and 52, 
respectively. 
Cognitive screening tools MMSE = Mini-Mental State Examination, AMT = Abbreviated Mental Test Score, 3-MS = The Modified Mini-Mental State 
Depression scales HAMD = Hamilton Depression Rating Scale, MADRS = Montgomery-Asberg Depression Scale, CES-D = Center for Epidemiologic Studies 
Depression Scale , GDS = Geriatric Depression Scale, BDI = Beck Depression Inventory, SCL-20 = Hopkins Symptom Checklist 
  
Table 2: Study characteristics 
Study year Outcome Setting 
Diagnostic 
criteria 
used for 
MDD 
Treatment 
condition(s) 
Comparator / control 
condition(s) 
Type of 
statistical 
analysis 
used for 
predictors S
tu
d
y 
d
u
ra
ti
o
n
 (
in
 
w
e
e
ks
) 
Source RCT 
Ackerman 1997 RES/REM practice DSM III Fluoxetine Placebo Regression 6 Tollefson et al. (1995) 
Ackerman 2000 RES/REM practice DSM III R Fluoxetine Placebo Regression 6 Tollefson et al. (1995) 
Adeoye 2000 RES practice DSM III R Bupropion 150mg Bupropion 75 mg Bivariate 3-11 Primary 
Alexopoulos 2005 REM practice DSM IV Care management Usual care Regression 72† Bruce et al. (2004) 
Alexopoulos 2014 SCORE practice DSM IV Personalised 
Intervention for 
depression and COPD 
Usual care Regression 52† Primary 
Alpert 2003 SCORE mixed DSM III R Sertraline Nortriptyline Regression 12 Bondareff et al. 
(2000) 
Andreescu 2007 RES practice DSM IV Pharmacotherapy +  
Clinical management / 
Placebo +  
Clinical management / 
Pharmacotherapy  + 
IPT / Placebo + IPT 
Placebo Survival 
analysis 
120 Reynolds et al. (2006) 
Andreescu 2009 RES practice DSM IV Pharmacotherapy +  
Clinical management / 
Placebo +  
Clinical management / 
Pharmacotherapy  + 
IPT / Placebo + IPT 
Placebo Bivariate 104† Reynolds et al. (2006) 
Azar 2011 REM practice DSM IV Integrated care model Enhance specialty 
referral model 
Regression 24† Krahn et al. (2006a) 
Banerjee 1996 SCORE practice AGECAT Psychogeriatric team Usual care Regression 24† Primary 
Bao 2011 SCORE practice DSM IV Care management Usual care Regression 96† Bruce et al. (2004) 
Beaudreau 2015 RES/REM practice DSM IV Problem solving 
therapy 
Supportive therapy ROC 
analysis 
12 Arean et al. (2010) 
Bjolseth 2015 REM practice DSM IV TR ECT bifrontal  ECT right unilateral Regression 12 Primary 
Bogner 2007 RES/REM practice DSM IV Care management Usual care Regression 16 Bruce et al. (2004) 
Bogner 2012 CAT practice DSM IV Care management Usual care Regression 96† Bruce et al. (2004) 
Bondareff 2000 SCORE community DSM III R Sertraline Nortriptyline Survival 
analysis 
12 Primary 
Cappeliez 2007 REM practice DSM IV 8 weeks treatment 
plan + problem solving 
intervention (optional) 
Usual care Bivariate 8 Primary 
Chan 2013 SCORE community N/A Life story book 
creation 
Visit Regression 8 Primary 
Chan 2014 SCORE community N/A Life story review Visit Regression 8 Primary 
Coon 2003 SCORE practice RDC CBT + Desipramine CBT alone Regression 16† Thompson et al. 
(2001) 
Evans 1997 RES practice GMS/ 
AGECAT 
Fluoxetine Placebo Regression 8 Evans et al. (1997a) 
Eyre 2016 REM practice DSM IV Methylphenidate + 
Citalopram 
Methylphenidate / 
Citalopram 
Bivariate 16 Lavretsky et al. (2015) 
Fields 2012 SCORE practice not 
specified 
Celecoxib/  
Naproxen sodium 
Placebo Regression 260† Lyketsos et al. (2007) 
Gasto 2003 REM practice DSM IV Venlafaxine Nortriptyline Bivariate 24 Primary 
Ghesquiere 2014 REM practice DSM IV Care management Usual care Regression 16† Bruce et al. (2004) 
Gildengers 2002 RES practice DSM IV Paroxetine Nortriptyline Regression 12 Reynolds et al. (1999) 
Gilman 2013 SCORE practice DSM IV Care management Usual care Regression 104† Bruce et al. (2004) 
Greenlee 2010 REM practice DSM IV IPT +  
Care management 
Care management Survival 
analysis 
16 Reynolds et al. (2010) 
Heun 2013 RES practice DSM IV TR Agomelatine Placebo Regression 8 Primary 
Hsu 2016 REM practice DSM IV Venlafaxine + 
Aripiprazole 
Venlafaxine Bivariate 12 Lenze et al. (2015) 
Jorge 2008 SCORE practice DSM IV rTMS Sham Regression 1.5† Primary 
Kaneriya 2016 REM practice DSM IV Venlafaxine + 
Aripiprazole 
Venlafaxine Regression 12 Lenze et al. (2015) 
Katon 2010 REM practice DSM IV Care management + 
activities + Problem 
Solving in Primary Care 
Usual care Regression 96† Unutzer et al. (2002) 
Kin 1997 RES practice DSM III Moclobemide Nortriptyline / Placebo Bivariate 7 Nair et al. (1995) 
Kok 2009a REM practice DSM IV Venlafaxine Nortriptyline Survival 
analysis 
12 Kok et al. (2007) 
Kok 2009b REM practice DSM IV Venlafaxine Nortriptyline ROC 
analysis 
12 Kok et al. (2007) 
Koran 1995 RES/REM practice DSM III R Fluoxetine Placebo Regression 6 Primary 
Korte 2012 SCORE practice MINI Life review therapy Usual care Regression 36 Korte et al. (2009) 
Krahn 2006 SCORE practice MINI Integrated care Enhanced specialty 
referral 
Regression 24 Levkoff et al. (2004)  
Krishnan 2001 RES practice DSM III R Sertraline/Nortriptyline Placebo Regression 12 Bondareff et al. 
(2000), Newhouse et 
al. (2000)  
Laidlaw 2008 SCORE practice DSM IV CBT Usual care ANCOVA 24† Primary 
Mavandadi 2007 SCORE practice DSM IV Integrated care Specialty referral care Regression 52† Krahn et al. (2006a) 
Morse 2005 RES practice SADS Nortriptyline+ IPT Placebo Survival 
analysis 
26 Reynolds et al. (1999) 
Mulsant 2001 RES practice DSM IV Nortriptyline Paroxetine Regression 12 Mulsant et al. (1999) 
Murphy 2013 SCORE practice DSM IV Mirtazapine Paroxetine Principal 
component 
8 Schatzberg et al. 
(2002) 
Narushima 2010 RES mixed DSM IV TR rTMS Placebo Regression 2 Primary 
Navarro 2001 REM practice DSM IV Citalopram Nortriptyline Bivariate 12 Primary 
Rapaport 2003 SCORE practice DSM IV Paroxetine CR/ 
Paroxetine IR 
Placebo Regression 12 Primary 
Raskin 2008 RES practice DSM IV Duloxetine Placebo Survival 
analysis 
8 Raskin et al. (2007) 
Riebe 2012 RES practice DSM IV Care management + 
Activities + Problem 
Solving in Primary Care 
Usual care Regression 52† Unutzer et al. (2002) 
Roose 2004 RES/REM mixed DSM IV Citalopram Placebo Regression 8 Primary 
Rosenthal 2005 SCORE practice DSM III R Antidepressants+ 
Clinical management+ 
Dialectical behaviour 
therapy 
Antidepressants + 
Clinical management 
Regression 28 Lynch et al. (2003) 
Salloway 2002 SCORE practice DSM IV Sertraline (old) / 
Citalopram (very old) 
Placebo Bivariate 8 Schneider et al. 
(2003) 
Sarginson 2010a RES practice DSM IV Mirtazapine Paroxetine Regression 8 Murphy et al. (2003), 
Schatzgerg et al. 
(2002)  
Sarginson 2010b REM practice DSM IV Mirtazapine Paroxetine Regression 8 Murphy et al. (2003), 
Schatzgerg et al. 
(2002)  
Schweizer 1998 SCORE practice DSM III R Buspirone / 
Imipramine 
Placebo Factorial 
analysis 
8 Primary 
Singh 1997 SCORE community DSM IV High intensity 
progressive resistance 
training 
Interactive health 
education program 
Regression 10 Primary 
Smagula 2016 SCORE practice DSM IV Venlafaxine + 
Aripiprazole 
Venlafaxine + Placebo Bivariate 12 Lenze et al. (2015) 
Small 1995 SCORE practice DSM III R Fluoxetine Placebo Regression 6 Tollefson et al. (1995) 
Sneed 2007 SCORE community DSM IV Citalopram Placebo Regression 8 Roose et al. (2004a) 
Sneed 2008 RES practice DSM IV Citalopram Placebo Regression 8 Roose et al. (2004a) 
Sneed 2011 REM mixed DSM IV Sertraline Nortriptyline Regression 12 Primary 
Steffens 2006 SCORE practice DSM IV Care management + 
Activities + Problem 
Solving in Primary Care 
Usual care Regression 96† Unutzer et al. (2002) 
Tan 1994 SCORE practice N/A Iofepramine Placebo Bivariate 5 Primary 
van Schaik 2006 RES practice PRIME-MD IPT Usual care Regression 24 Primary 
Volz 1995 CAT practice DSM III Brofaromine Imipramine Bivariate 8 Moller and Volz 
(1992,1993)  
Zanetidou 2016 REM practice DSM IV Sertraline +  
Physical exercise 
Sertraline Regression 24† Belvederi M. et al. 
(2015) 
 
Note:  
Outcome RES = response, REM = remission, SCORE = score on depression questionnaire, CAT = depression categories (e.g. high persistent, high decline and 
low decline) 
Diagnostic criteria DSM = Diagnostic and Statistical Manual of Mental Disorders, PRIME-MD = Primary Care Evaluation of Mental Disorders screening 
questionaire for depressive symptoms, MINI = The M.I.N.I. International Neuropsychiatric Interview, SADS= Schedule for Affective Disorders and 
Schizophrenia-Lifetime Version, GMS/AGECAT = Geriatric Mental Scale/AGECAT 
Intervention CBT = Cognitive behavioural therapy, IPT = Interpersonal psychotherapy, ECT= Electroconvulsive therapy, rTMS = repetitive Transcranial 
Magnetic Stimulation 
† = data calculated from months or years to weeks by multiply by 4 and 52, respectively.  
Table 3: Statistically significant predictors of response, remission and depression score or category 
Factors Predictors  Response  Remission  Score/Category 
Demographic     
Ethnic Black +  Ackerman 1997a 
Ackerman 2000a 
    
 White     + Bao 2011c  
Smagula 2016a 
Age Older age   + Zanetidou 2016d + Bogner 2012c 
  - Jorge 2008d - Riebe 2012c - Bondareff 2000a  
Chan 2013b 
Gender Female - Raskin 2008a - Raskin 2008a   
Marital status Being married + Bogner 2012c   - Lailaw 2008b 
Education Higher level     + Gilman 2013c 
      - Bao 2011c 
Socioeconomic Financial strain     - Gilman 2013c 
 Social support     + Gilman 2013c 
        
Clinical        
Depression Baseline severity + Roose 2004a 
van Schaik 2006b 
  + Tan 1994a 
  -  Mulsant 2001a  - Ackerman 1997a 
Alexopoulos 2005c 
Azar 2011c  
Bjolseth 2015d 
Capaeliez 2007c 
Ghesquier 2014c 
Katon 2010c  
Kok 2009aa 
Raskin 2008a 
- Banerjee 1996c 
Coon 2007b  
Mavandadi 2007c  
Rosenthal 2005b 
 
 Early improvement + Koran 1995a 
Kok 2009ba 
+ Koran 1995a + Volz 1995a 
 Current episode duration - Mulsant 2001a - Kok 2009aa - Rapaport 2003a 
 Severe group (endogenous, psychotic,  
severe inhibition) 
  + Navarro 2001a   
 Age of initial onset     + Rosenthal 2005b 
 First episode     - Banerjee 1996c 
 Previous antidepressant failure   - Hsu 2016a   
Anxiety Baseline severity - Ackerman 2000a 
Andreescu 2007abc  
- Ackerman 1997a 
Alexopoulos 2005c  
Azar 2011c  
Kaneriya 2016a 
  
Zanetidou 2016d 
 Severity at 6 week of treatment   - Greenlee 2010b   
 Worry and panic - Andreescu 2009abc     
Other symptoms Psychotic - Bjolseth 2015d + Bjolseth 2015d   
 Suicidal ideation     - Bogner 2012c 
 Psychomotor retardation   + Zanetidou 2016d   
 Somnolence + Ackerman 2000a     
 Somatisation - Ackerman 1997a     
 Somatic symptoms   - Cappeliez 2007c   
 Hopelessness   - Alexopoulos 2005c   
 Limitation of emotional function   - Alexopoulos 2005c   
 Perceived adequacy of emotional and 
instrumental support 
+ Cappeliez 2007c     
 Engagement in pleasant activity   + Riebe 2012c   
Personality Cluster C personality disorder - Morse 2005abc     
 Extraversion trait     + Korte 2012b 
        
Physical Physical illness -  Evans 1997a - Alexopoulos 2005c - Bogner 2012c 
Azar 2011c Chan 2014b  
Gilman 2013c 
Krahn 2006c 
 Pain   - Raskin 2008a - Mavandadi 2007c 
 Cerebrovascular disease - Evans 1997a  
Raskin 2008a 
    
 Polypharmacy   + Zanetidou 2016d   
 Headache + Ackerman 2000a     
        
 Limitation of physical function   - Alexopoulos 2005c   
 Dyspnea-related disability     - Alexopoulos 2014c 
 Maximum Oxygen uptake (VO2max)   + Zanetidou 2016d   
Investigation        
Blood Bupropion plasma concentration + Adeoye 2000 a     
 Erythrobupropion and threobupropion - Adeoye 2000 a     
 Folic level     + Alpert 2003 a 
 Cortisol level - Kin 1997a     
 Dexamethasone suppression test: 
suppressor 
+ Kin 1997 a     
EEG Low-theta power in subgenual ACC cluster + Narushima 2010d     
Genetic rs1360780 -  Sarginson 2012b a     
 rs3800373 -  Sarginson 2012b a     
 rs2032583 C carrier   +  Sarginson 2012a a   
 rs2235040 A carrier   +  Sarginson 2012a a   
 BDNF variant     ? Murphy 2013 a 
 CREB1 variant     ? Murphy 2013 a 
 HLA-DRB5   ? Eyre 2016 a   
 SELENBP1   ? Eyre 2016 a   
 LOC388588   ? Eyre 2016 a   
Neuropsychological        
General cognition  MMSE >23 + Evans 1997 a     
 Cognitive decline     - Steffens 2006c 
 Attention     + Smagula 2016 a 
 Immediate memory     + Smagula 2016 a 
Executive function Response inhibition in Stroop - Bogner 2007c - Bogner 2007c - Sneed 2007 a 
 Trail Making Test :set shifting + Beaudreau 2015b + Kaneriya 2016 a + Smagula 2016 a 
        
Brain imaging        
 Deep white matter hyperintensity - Sneed 2011 a     
 Periventricular hyperintensity - Sneed 2011 a     
 Total hyperintensity volume - Sneed 2011 a     
 Gray matter volume in left and  
right frontal brain region 
  + Jorge 2008d   
Note: + = positive prediction to outcome, - = negative prediction to outcome, ? = direction of prediction to outcome was not identified. 
Subscript: a= pharmacologic study, b=psychological therapy study, c= care management study, d= rTMS or ECT study, abc= combined pharmacotherapy, 
psychological and care management study. 
 
  
 Table 4: Results of meta-analysis for each predictor variable of good outcome. 
 
 
 
Predictor Study 
Pooled 
OR 
95% CI z p Q p 
I2 
(%) 
Tau2 
Egger 
bias 
estimate 
95% CI p 
Age 6 0.783 0.457 1.342 -0.888 0.374 24.31 <.001 79.4 0.3102 -0.633 -3.668 2.403 0.594 
Baseline anxiety 7 0.447 0.271 0.736 -3.163 0.002 32.70 <.001 81.7 0.2752 2.467 -3.093 -1.841 <0.001 
Baseline depression 14 0.886 0.833 0.943 -3.828 <0.001 75.97 <.001 82.9 0.0053 -1.648 -3.111 -0.185 0.030 
Trail making test 3 2.247 1.405 3.593 3.381 0.001 1.23 0.540 0.0 0.0000 0.944 -9.759 11.647 0.464 
Physical illness 5 0.843 0.712 0.998 -1.980 0.048 35.62 <.001 88.8 0.0208 -2.950 -5.777 -0.123 0.045 
Table 5: Results of subgroup meta-analyses by treatment type for each predictor. 
Predictor 
 Treatment type 
No. of 
study 
Pooled OR (95% CI) Overall effect: 
z (p value) 
I2 % (p value) Publication 
bias: Egger 
bias estimate 
(p value) 
Subgroup 
differences†: 
I2 (p value) 
Age      82.9 (0.003) 
 Biological 3 0.447 (0.221, 0.903) 2.24(0.025) 59.3 (0.086) -0.355 (0.976)  
 Psychosocial 1 0.973 (0.457, 1.342) 0.04 (0.970) 87.0 (0.006) N/A  
 Biological plus psychosocial 2 1.428 (0.593, 3.440) 0.79 (0.427) N/A UC  
       
Baseline depression      86.0 (0.001) 
 Biological 5 0.786 (0.575, 1.075) 1.51 (0.132) 85.1 (<0.001) -0.719 (0.709)  
 Psychosocial 2 0.472 (0.187, 1.192) 1.59 (0.112) 49.5 (0.159) UC  
 Biological plus psychosocial 7 0.922 (0.874, 0.973) 2.98 (0.003) 81.8 (<0.001) -2.182 (0.065)  
       
Baseline anxiety      94.5 (<0.001) 
 Biological 4 0.273 (0.154, 0.484) 4.44 (<0.001) 0 (0.752) -1.346 (0.311)  
 Psychosocial 0 N/A N/A N/A N/A  
 Biological plus psychosocial 3 0.656 (0.399, 1.079) 1.66 (0.097) 85.1 (0.001) -2.941 (0.052)  
       
Physical illness      95.5 (<0.001) 
 Biological 0 N/A N/A N/A N/A  
 Psychosocial 1 0.016 (0.003, 0.089) 4.76 (<0.001) N/A N/A  
 Biological plus psychosocial 4 0.900 (0.808, 1.002) 1.91 (0.056) 77.6 (0.004) -2.147 (0.115)  
       
Executive functioning (Trail Making Test)      18.0 (0.269) 
 Biological 2 2.080 (1.276, 3.391) 2.94 (0.003) 0 (0.930) UC  
 Psychosocial 1 5.571 (1.042, 29.790) 2.01 (0.045) N/A UC  
 Biological plus psychosocial 0 N/A N/A N/A N/A  
       
 
Note:   Biological treatment type consisted of data from pharmacological trials and rTMS/ECT trials. 
  Psychosocial treatment type consisted of data from psychological treatment trials.  
  Biological plus psychosocial treatment type consisted of data from care management and combined treatment trials. 
 † Overall test for heterogeneity between subgroup. Bonferroni-corrected alpha level of 0.01, adjusted for the number of treatment type 
subgroup analyses. 
 N/A is for not available. UC is for unable to calculate. 
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